Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial
Zulfa Omer(University of Cincinnati), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Allison Winter(Cleveland Clinic), Prioty Islam(Kettering University), Talha Munir(Leeds Teaching Hospitals NHS Trust), Michał Kwiatek(Institute of Plant Genetics, Polish Academy of Sciences), Karan Dixit(Northwestern University), Danielle M. Brander(Duke University), Sarah G. Injac(Baylor College of Medicine), Jeffery Smith(University of Liverpool), Iwona Hus(Medical University of Lublin), Michael Tees(Sarah Cannon), Joanna Romejko‐Jarosińska(National Institute of Oncology), Sebastian Grosicki(Medical University of Silesia), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), John C. Byrd(University of Cincinnati), Francesco Forconi(University of Leeds), Dima El‐Sharkawi(Royal Marsden Hospital), Alvaro J. Alencar(University of Miami), Nirav N. Shah(Medical College of Wisconsin), Mary Gleeson(Sarah Cannon Research Institute), Graham P. Collins(Churchill Hospital), Thorsten Zenz(German Cancer Research Center), Jane Robertson(AstraZeneca (United Kingdom)), Jonathon B. Cohen(Emory University)
Cited by 3
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453